Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? - Wikidata - awgldk - TriplyDB

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

http://www.wikidata.org/entity/Q38682012

about

New directions for pharmacotherapy in the treatment of acute coronary syndrome.Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.

P2860

Q38817144-8AEC8199-40D5-4CE9-8961-C82C37A45223 Q53084647-D19A97E9-1643-4F80-B2BE-00FCA4B44417

P2860

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

http://www.wikidata.org/entity/Q38682012

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

@en

type

label

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

@en

prefLabel

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

@en

P1433

Q38682012-6F88A8A0-5E0B-4628-838D-2F177AE2B9FF

P1476

Q38682012-6ABA1AA2-D35C-4BEC-B64C-083FECD15F56

P2093

Q38682012-4C44EEA8-EC5D-41C5-8DEA-0214456277A5

Q38682012-FC64EA6D-E45F-42F1-AAA6-440C19D42917

P2860

Q38682012-04ADCF67-0EF1-428A-A0C3-02F89F564735

Q38682012-0670E55F-2F37-4458-89D9-8BF21E072037

Q38682012-0834F3F1-75C2-4A4C-8D64-90DD817F561E

Q38682012-090234B5-5817-429A-BDB5-D88E3BA00CB7

Q38682012-0CBF7633-BB53-456F-B929-E7F4BE06C4DB

Q38682012-10DCFAD9-4702-4815-8869-27984664DF2C

Q38682012-13BF28A6-0474-428F-B96E-0E0764C61E55

Q38682012-1F656525-A982-48DD-8150-2F36ADC48E5B

Q38682012-1F819248-9347-4457-8A1B-0342ABD699B5

Q38682012-210B97AA-FA6A-444C-8704-9ECAB85080B3

P304

Q38682012-C660DC15-7E11-49BB-8256-84FCE6FDD23B

P31

Q38682012-380CD5C4-1FE1-4731-BEB5-0CF31BAD10E3

P356

Q38682012-F45476CC-7BD3-42B8-92FF-A3B40F4625EA

P433

Q38682012-7AA4715E-C85A-4E2D-8E3C-F0F83FADF191

P478

Q38682012-61FFCA09-159A-4742-B7B1-2324622FE588

P50

Q38682012-15DA9A61-CE90-4E7C-88A9-FE8F0B09C20B

P577

Q38682012-80D47FA7-245C-41D0-94BF-CEFC4C6CE9EA

P5875

Q38682012-246613F9-DE5D-4019-AA73-3F7339130AD4

P698

Q38682012-DA983173-5A40-4243-AB4C-A530206A74D0

P356

P1433

European Heart Journal

P1476

Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

@en

P2093

Dirk Sibbing

http://www.w3.org/2001/XMLSchema#string

Peter B Berger

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Identification of the platelet ADP receptor targeted by antithrombotic drugs

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

P304

1284-1295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV717

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288817460

http://www.w3.org/2001/XMLSchema#string

P698

26712838

http://www.w3.org/2001/XMLSchema#string